Back to search

Article

Genetic and Immunological Characterization of Advanced NSCLC with SWItch/Sucrose NonFermentable Families Genetic Alterations and Its Impact on Response to Immune Checkpoint Inhibitors

2022-10-19

Abstract excerpt

<h4>Background: </h4> Genetic alterations involving the SWItch/Sucrose NonFermentable (SWI/SNF) family are highly prevalent but understudied in non-small cell lung cancer (NSCLC), especially its controversial roles in the implication of immunotherapy. We aimed to comprehensively characterize the clinicopathologic features of SWI/SNF mutation and to investigate its impact on immunotherapy outcomes among NSCLC patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6d9f163c-48df-5f49-83a5-178c466ec710
DOI
10.21203/rs.3.rs-2171791/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genetic and Immunological Characterization of Advanced NSCLC with SWItch/Sucrose NonFermentable Families Genetic Alterations and Its Impact on Response to Immune Checkpoint InhibitorsDOI 10.21203/rs.3.rs-2171791/v1
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.Semantic proximity
Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.Semantic proximity
Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.Semantic proximity
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 casesSemantic proximity
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 casesSemantic proximity
ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.Semantic proximity
Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panelSemantic proximity
Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC).Semantic proximity
SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response.Semantic proximity
<i>STK11</i> and <i>KEAP1</i> Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma CohortSemantic proximity
Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.Semantic proximity
Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.Semantic proximity
Select a neighboring publication to make it the new centre.